Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis
Year: 2025
Type: article
Abstract: BACKGROUND: The impact of body weight on disability progression rates among patients receiving ofatumumab was not evaluated yet. METHODS: Among patients from a multicentre prospective cohort, baseline demographics were compared among body mass index (BMI) quartiles as well as proportions of clinical relapses, MRI lesions and disability worsening during follow-up. RESULTS: ; adjusted HR: 3.33 (95% CI: 1.72 to 6.42; p<0.001). Relapse-associated worsening was not substantially different among relapsing patients from different BMI strata (HR: 1.19 (95% CI: 0.40 to 3.52; p=0.750)). Yet, progression independent from relapse activity was more likely in patients from 4th BMI quartile (HR: 2.00 (95% CI: 1.47 to 2.70; p<0.001)).Body weight (4th body weight quartile: ≥84.5 kg) was not associated with disability worsening (adjusted HR: 1.91 (95% CI: 0.97 to 3.76; p=0.060). Ofatumumab serum levels were lower in patients with higher BMI as well. CONCLUSIONS: ). This was associated with lower ofatumumab serum levels. Since body weight itself was not predictive, we assume that body fat composition is critical for ofatumumab effectiveness.
Authors: Pia Winter, Franziska Axhausen, Stephanie Wolff, Alice Grizzle Willison, Saskia Räuber, Franz Felix Konen, Stefanie Schreiber, Philipp Schwenkenbecher, Ramona Hagler, Tobias Ruck, Hagen B Huttner, Christoph Kleinschnitz, Mark Pawlitzki, Thomas Skripuletz, Refik Pul, Sven G Meuth, Steffen Pfeuffer
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4408230637